Based in Cambridge, UK, we are making better medicines by continually improving our antibody discovery technologiesLearn more
Our unique technologies drive the rapid development of effective, human antibody-based drugs across our four main therapeutic areas - immuno-oncology, inflammation, haematology and infectious disease.View our pipeline
Join us in developing tomorrow's medicines: we're driven by passion for better healthcare and by compassion to make a difference. Join our experienced and successful team and help us to realise our aims.View our vacancies
Two Company-sponsored oral and poster abstracts to be presented on KY1049 and IntelliSelect® Bispecifics platform
Clinical trial initiated in February 2019 in the U.S., MD Anderson Cancer Center and Sarah Cannon Research Institute Phase ...
Kymab submits confidential draft registration statement for proposed initial public offering in the United States
Cambridge, UK; April 8, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced t...
7 Aug 2019 - 8 Aug 2019 | Boston, MA, USA
View event details